INTRODUCTION
============

Damage to the immunological and structural barrier of the gastrointestinal (GI) tract which occurs during acute HIV infection of humans and SIV infection of Asian macaques leads to translocation of microbial products from the lumen of the GI tract into circulation \[[@R1]--[@R3]\]. Significant loss of GI tract-resident CD4^+^ T cells \[[@R4]\], decreased production of IL-17 and IL-22 effector cytokines by GI tract-resident lymphocytes \[[@R5]--[@R7]\], alteration to the landscape of antigen presenting cells \[[@R5], [@R8]\], and epithelial cell apoptosis with loss of epithelial integrity \[[@R2], [@R9], [@R10]\] all contribute to epithelial barrier damage and, thus, microbial translocation in HIV/SIV infected individuals. Microbial products directly stimulate the immune system and, therefore, contribute to systemic inflammation in immunodeficiency lentiviral infections. While microbial translocation is one cause of systemic inflammation, the degree to which microbial translocation contributes to inflammation relative to HIV/SIV replication, and to frequently co-existing co-infections, in immunocom-promised individuals is not fully known. The contribution of HIV/SIV to inflammation can be assessed, to a large degree, by treating people living with HIV (PLWH) and SIV-infected NHPs with antiretroviral therapy (ART). Indeed, after administration of ART systemic inflammation decreases but remains elevated relative to healthy humans and SIV-uninfected NHPs. Residual inflammation observed in ART-treated PLWH and SIV-infected NHPs is associated with increased morbidity and mortality as compared to uninfected, population controls \[[@R11]--[@R14]\]. Thus, there is great interest in understanding the contribution of microbial translocation to this residual inflammation.

Measurement of the degree of microbial translocation occurring *in vivo* has been difficult. Bacterial DNA can be detected by quantitative PCR using primers which detect conserved sequences in the DNA that encode bacterial ribosomal RNA and elevated levels of bacterial DNA have been observed in PLWH \[[@R15]--[@R17]\]. The sensitivity of this assay is very low; however extracellular endonucleases in plasma and tissues can degrade extracellular DNA \[[@R18]\]. Additionally, bacterial DNA contamination is common in biomedical science which can confound the assay. The bacterial cell wall component lipopolysaccharide (LPS) can also be measured in biological materials by the limulus amebocyte lysate (LAL) assay. This assay takes advantage of an enzymatic reaction within the horseshoe crab (limulus) coagulation system that occurs in the presence of LPS. LPS levels are detectable in the pg/ml range with the LAL assay \[[@R1]\]. However, the ability of this assay to reliably detect LPS is greatly influenced by the presence of plasma proteins, such as high-density lipoproteins that result in its hepatic clearance and natural antibodies that recognize LPS, both of which can shield LPS from the LAL enzymatic reactions \[[@R19]\]. Thus, the ability to reliably measure systemic bacterial DNA and plasma LPS is highly variable.

A third approach to ascertaining levels of microbial translocation involves immunohistochemical staining for microbial products in paraffin-embedded tissue sections \[[@R2]\]. This requires tissues obtained at necropsy or after invasive biopsy procedures but allows for unambiguous determination of where microbial products reside, whether they co-locate with proinflammatory mediators, how effectively they are being cleared by phagocytes, and can be used to precisely enumerate products of microbial translocation with quantitative image analysis \[[@R2]\]. However, given the amount of tissue required, this approach is not easily adapted to large cohorts, or to longitudinal studies. Thus, while there is considerable interest in understanding the causes and consequences of microbial translocation, assays for precise quantitative determination remain undefined.

As a surrogate to measuring microbial products directly, many studies measure host proteins made, predominantly, in response to microbial antigenic stimulation. Commonly, plasma levels of soluble CD14 (sCD14, produced by myeloid cells after stimulation by LPS), lipopolysaccha-ride-binding protein (LBP, produced by hepatocytes after LPS-stimulation), and/or natural antibodies directed against LPS core antigen (EndoCAb) \[[@R20]\] are used as surrogate biomarkers. Of these, sCD14 is most commonly measured as an estimate of the level of microbial translocation given that it can be easily measured in plasma \[[@R20]\]. With TLR4, CD14 is part of the LPS receptor. Myeloid cells that are stimulated with LPS produce and secrete sCD14 and circulating sCD14 levels correspond to the degree to which myeloid cells were stimulated with LPS *in vivo* \[[@R21]\]. However, LPS is not the only ligand for CD14/TLR4 and the degree to which sCD14 levels accurately reflect microbial translocation in PLWH has been disputed \[[@R22]--[@R24]\]. RAGE shares common ligands and signaling pathways with the CD14/TLR4 complex - including high mobility group box protein 1 (HMGB1), a protein produced during cellular stress and a putative cause of chronic inflammation \[[@R25]--[@R27]\]. To understand the degree to which levels of HMGB1 and RAGE, proteins secreted during cellular stress, associate with sCD14 in PLWH and SIV-infected NHPs, here we measured plasma levels of RAGE, HMGB1, sCD14 and other markers associated with damage to the epithelial barrier of the GI tract such as intestinal fatty acid binding protein (IFABP) in cohorts of ART naïve and ART-treated PLWH and SIV-uninfected and SIV-infected NHPs. We find that neither HMGB1 nor RAGE are likely to be significant causes of elevated sCD14 levels observed routinely in progressively infected PLWH and SIV-infected NHPs.

METHODS
=======

Study Subjects and Samples
--------------------------

Cohorts for this study consisted of longitudinal samples from 34 PLWH sampled prior to administration of ART and either one or four years after ([Supplementary Table 1](#TS1){ref-type="table"}); 9 pigtail macaque monkeys (PTs) and 11 rhesus macaque monkeys (RMs) followed longitudinally pre-SIV infection and during acute (day 28 or 29 post-SIV infection) and chronic infection (day 197 or later post-SIV infection) ([Supplementary Tables 2](#TS2){ref-type="table"} and [3](#TS3){ref-type="table"}). All NHPs in this study were experimentally infected with SIVmac239.

All human study participants provided written informed consent prior to the study under institutional review board-approved protocol: Immune reconstitution syndrome in HIV-infected patients taking antiretroviral therapy (IRIS, NCT00286767) to NIAID, and protocol number 1011003018, Pulmonary CD4 T cell repopulation in immune reconstitution syndrome to the Indiana University.

All NHPs included in this study were housed and cared for in accordance with standards put forth by the American Association for the Accreditation of Laboratory Animal Care (AAALAC). All procedures were performed with approval and in accordance with the Institutional Animal Care and Use Committee within the National Institute of Allergy and Infectious Diseases (animal study protocol LVD26).

Plasma and peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by standard density centrifugation and frozen (plasma) or cryopreserved (PBMC) so that all longitudinal study samples could be analyzed together.

Measurement of Cellular Stress, Microbial Translocation, and Epithelial Damage Biomarkers
-----------------------------------------------------------------------------------------

We measured plasma levels of HMGB1, sCD14, RAGE, IFABP, and zonulin by enzyme-linked immunosorbent assay (ELISA) in human and non-human primate samples ([Table 1](#T1){ref-type="table"}). All markers were analyzed according to the manufacturer\'s instructions.

  Analyte   Species         Company             Catalog           Plasma Dilution
  --------- --------------- ------------------- ----------------- -----------------
  HMGB1     Human, RM, PT   Antibodies Online   \#abx151824       1:20
  sCD14     Human, RM, PT   R&D Systems         \#DC140           1:300
  RAGE      Human           R&D Systems         \#DRG00           undiluted
  RAGE      RM, PT          My Biosource        \#MBS746886       undiluted
  IFABP     Human           Hycult              \#HK406-02        1:4
  IFABP     RM, PT          My Biosource        \#MBS740424       undiluted
  Zonulin   Human, RM, PT   Alpco               \#30-ZONSHU-E01   1:20

Plasma Viral Load and CD4 T Cell Assessment
-------------------------------------------

SIV viral RNA levels in plasma were determined by real-time RT-PCR (ABI Prism 7900 sequence detection system; Applied Biosystems) using primer pairs corresponding to SIV~mac239~ gag gene sequences (forward, nucleotides 1181--1208, and reverse, 1338-1317). HIV viral RNA levels in plasma were determined by either a RTPCR COBAS 1.5 HIV Assay (Roche, with a lower limit of detection of 50 HIV copies/mL) or a RealTime HIV Assay (Abbott, with a lower limit of detection of 40 HIV copies/mL).

CD4^+^ T-cell counts were calculated from complete blood counts and CD4^+^ lymphocyte percentages determined via flow cytometric phenotypic profiling of PBMC samples from the same time-points.

STATISTICAL ANALYSES
====================

All statistical analyses were performed using Prism v8.0 (GraphPad Software). The Wilcoxon *t* test (matched pairs, two-way, nonparametric) was used for all analyses between longitudinal samples ([Figure 1](#F1){ref-type="fig"}). All correlational analyses were performed using the Spearman rank test ([Figures 2](#F2){ref-type="fig"}-[4](#F4){ref-type="fig"}). Given correlations were measured in three different primate species, multiple comparison corrections were not considered.

![**Plasma biomarker levels in NHPs during SIV infection and in people living with HIV (PLWH) following ART.** (A-E) Plasma levels of biomarker analytes in NHPs (n = 20, graphs on the left, with PTs in blue and RMs in red) pre-SIV infection, during acute-SIV infection, and during chronic infection; and PLWH (n = 34, graphs on the right) pre- and post-ART treatment for (A) sCD14, (B) HMGB1, (C) RAGE, (D) IFABP, (E) Zonulin, and (F) Reg3α. Lines connect the same study participant over time. Wilcoxon t tests were used to determine each P-value. Δ values represent the mean fold-change between timepoints.](pai-5-068-g001){#F1}

RESULTS
=======

Study Participant Cohorts
-------------------------

Here we assayed samples from PLWH pre-treatment and following ART (n=34) and Asian macaque NHPs prior to and throughout SIV-infection (total n = 20, 9 pigtailed macaques, PTs, and 11 rhesus macaques, RMs) ([Supplementary Tables 1](#TS1){ref-type="table"}-[3](#TS3){ref-type="table"}). PLWH had a mean CD4^+^ count of 75 cells/μl (range 0 to 444 cells/μl) prior to ART and exhibited a significant increase following ART (*P* \< 0.0001, mean count = 385 cells/μl, range 149 to 759 cells/μl). The PLWH cohort had a mean plasma viral load of 127,698 copies (c)/mL (ranging from \< 50 (2 patients) to 609,435 c/mL), with all of the study participants having viral loads below or close to the limit of detection after ART of at least 1 year ([Supplemental Table 1](#TS1){ref-type="table"}).

SIV-infected cohorts had a mean acute plasma viral load of 584,338 c/mL (ranging from 1,736 to 2,403,815 c/mL) and mean chronic viral load of 1,267,104 c/mL (ranging from 621 to 7,200,000 c/mL). These SIV-infected cohorts demonstrated a decline in CD4^+^ T cell counts from pre-SIV infection through acute and chronic SIV-infection (with mean CD4^+^ T cell counts of 758 cells/μl for pre-, 325 cells/μl acute-, and 127 cells/μl chronic-SIV timepoints) ([Supplemental Tables 2](#TS2){ref-type="table"}-[3](#TS3){ref-type="table"}).

Plasma Biomarker Levels
-----------------------

Consistent with several previous studies, we observed a marked increase in plasma sCD14 levels in SIV-infected NHPs from pre-SIV to chronic-SIV and from acute to chronic SIV-infection timepoints ([Figure 1A](#F1){ref-type="fig"}, *P* = 0.04 and *P* \< 0.0001) and significant decreases in the plasma levels of sCD14 in plasma of PLWH following antiretroviral treatment (ART, *P* = 0.0008, [Figure 1A](#F1){ref-type="fig"}) \[[@R1], [@R3], [@R15]\]. Interestingly, sCD14 levels decreased during acute SIV infection ([Figure 1A](#F1){ref-type="fig"}). While we have previously seen these levels to be moderately elevated during acute HIV infection \[[@R1]\], this apparent discrepancy is likely due to the well controlled longtidutinal analysis we were able to perform in NHPs. In order to determine if HMGB1 plasma levels followed similar patterns as sCD14 plasma levels during HIV/SIV infection and following ART, we next assayed this analyte in the same cohorts ([Figure 1B](#F1){ref-type="fig"}). We found that HMGB1 levels were elevated from pre-SIV infection in both acute (*P* = 0.04) and chronic (*P* = 0.001) SIV infection timepoints; however, HMGB1 was not increased between acute and chronic SIV infection. In PLWH, plasma levels of HMGB1 demonstrated no significant consistent changes following ART ([Figure 1B](#F1){ref-type="fig"}). Thus, alterations in the levels of sCD14 and HMGB1 were not consistent across SIV infection or after administration of ART in PLWH.

We next assessed levels of RAGE in plasma given its ability to induce sCD14 *in vitro* and *in vivo*. In Asian macaques levels of RAGE were entirely unaffected over the course of SIV infection ([Figure 1C](#F1){ref-type="fig"}). In PLWH, RAGE levels significantly decreased after administration of ART (*P* = 0.01, [Figure 1C](#F1){ref-type="fig"}). Thus, neither HMGB1 nor RAGE levels mirrored sCD14 level alterations which occur over the course of SIV infection of Asian macaques. However, RAGE levels in PLWH did follow a decreasing trend similar to that seen for sCD14 plasma levels after administration of ART in PLWH (*P* = 0.01, [Figure 1C](#F1){ref-type="fig"}).

Microbial translocation occurs when there is a loss of/or damage to the GI tract epithelial barrier. Epithelial damage is thought to result in rapid release of epithelial fatty acid binding proteins and extracellular proteins involved in epithelial tight junctions into circulation \[[@R28], [@R29]\]. To assess the reliability of proteins released during epithelial damage as potential markers of microbial translocation, we measured plasma levels of IFABP and zonulin, a protein that functions to maintain intercellular junctions, in plasma. As Asian macaques progressed from acute to chronic infection, both IFABP (*P* = 0.02, [Figure 1D](#F1){ref-type="fig"}) and zonulin (*P* = 0.03, [Figure 1E](#F1){ref-type="fig"}) increased. In PLWH, 1-4 years of ART treatment was insufficient to result in significant decreases in these markers of intestinal damage ([Figure 1D](#F1){ref-type="fig"}-[E](#F1){ref-type="fig"}) consistent with previous reports \[[@R30]\]. In fact, IFABP levels actually tended to increase (*P* = 0.08, [Figure 1D](#F1){ref-type="fig"}), likely due to increased epithelial cell turnover to repair the barrier. These data suggest that prolonged ART does not completely reduce GI tract damage observed in PLWH. Like HMGB1 and RAGE, these results did not track with sCD14 dynamics.

Another systemic biomarker which has recently been suggested to be associated with microbial translocation is Regenerating islet-derived protein 3α (Reg3α), an antimicrobial peptide produced by the GI tract epithelium \[[@R31]\]. Plasma levels of Reg3α have been shown to be elevated in chronic HIV infection and to correlate with plasma levels of lipopolysaccharide, pro-inflammatory cytokines, and percentages of activated CD4^+^ and CD8^+^ T cells \[[@R32]\]. Surprisingly, in our cohort of Asian macaques, plasma levels of Reg3α were unchanged during acute infection as compared to pre-infection levels, and actually decreased into chronic infection (*P* = 0.01, [Figure 1F](#F1){ref-type="fig"}). Moreover, we found no significant differences in circulating plasma levels of Reg3α in our human cohort following ART ([Figure 1F](#F1){ref-type="fig"}), while previous reports suggested these levels decrease in plasma of PLWH treated with ART \[[@R32]\].

Biomarker Associations
----------------------

Although markers of cellular stress, HMGB1 and RAGE, did not mirror sCD14 dynamics over the course of SIV infection or following ART in PLWH, we sought to determine if either analyte correlated with sCD14 or systemic levels of gut barrier damage. Positive associations would be supportive of their direct role in production of sCD14 *in vivo*. Even though HMGB1 levels were not decreased in PLWH treated with ART, changes over time in sCD14 trended towards a positive correlation with HMGB1 (human results in black r = 0.3303, *P* = 0.0564, [Figure 2A](#F2){ref-type="fig"}). This association was not observed in either NHP species (RM results shown in red; PT results shown in blue [Figure 2A](#F2){ref-type="fig"}). Interestingly, although longitudinal analysis of human plasma levels of RAGE trended consistently with sCD14 systemic plasma levels ([Figure 1A](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}), there were no significant correlations between changes in RAGE plasma level changes and longitudinal changes in sCD14 levels in either humans or NHPs ([Figure 2B](#F2){ref-type="fig"}). sCD14 levels were not associated with IFABP or zonulin levels in any primate species ([Figure 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}).

![**Plasma biomarker associations.** (A-I) Correlational analyses between longitudinal changes in plasma biomarkers in humans (black), RMs (red), and PTs (blue). All associations were analyzed using the Spearman rank test.](pai-5-068-g002){#F2}

We next extended this analysis to determine if changes in HMGB1 or RAGE were associated with markers of GI tract damage. While HMGB1 and RAGE can both be elevated as a result of cellular damage, these were not associated with one another in any of the primate species we studied ([Figure 2E](#F2){ref-type="fig"}). We did find strong associations between changes in plasma levels of RAGE and IFABP in both NHP groups (RM r = 0.83 and *P* = 0.0025; PT r = 0.85 and *P* = 0.0052, [Figure 2F](#F2){ref-type="fig"}) with no such association being observed in our human cohort. However, changes in RAGE did not associate with change in zonulin levels in either NHP cohort ([Figure 2G](#F2){ref-type="fig"}). Furthermore, changes in HMGB1 plasma levels did not correlate with either of the markers of epithelial damage we assayed (zonulin [Figure 2H](#F2){ref-type="fig"} and IFABP [Figure 2I](#F2){ref-type="fig"}). From these analyses, the data suggest that in progressive HIV/SIV infections neither HMGB1 nor RAGE contribute to elevated levels of biomarkers used as surrogates for microbial translocation.

Biomarker Associations with Canonical Measures of HIV/SIV Disease Progression
-----------------------------------------------------------------------------

We next determined whether canonical measures of HIV/SIV disease progression were associated with levels of any plasma biomarkers we studied. In particular, we studied associations with changes in CD4^+^ T cell counts ([Figure 3](#F3){ref-type="fig"}) and changes in plasma viral load ([Figure 4](#F4){ref-type="fig"}) over time. For PLWH we looked at the change in value from chronic infection to post-ART (Δ ART/chronic baseline), while for NHPs we looked at the change in values from pre- to chronic SIV-infection (Δ chronic/pre). Among the five studied biomarkers, only HMGB1 ([Figure 3B](#F3){ref-type="fig"}) and RAGE ([Figure 3C](#F3){ref-type="fig"}) showed correlations with changes in the numbers of CD4^+^ T cells in peripheral blood; however these associations were seen only in the PT cohort- no other correlations were observed.

![**Plasma biomarker associations with CD4 T cell frequencies.** (A-E) Correlational analyses between changes in CD4^+^ T cell numbers in peripheral blood and changes in plasma biomarkers in humans (black), RMs (red), and PTs (blue) for (A) sCD14, (B) HMGB1, (C) RAGE), (D) IFABP, and (E) Zonulin. All associations were analyzed using the Spearman rank test.](pai-5-068-g003){#F3}

Lastly, direct or indirect effects of viral components (such as viral RNA) can be directly stimulatory to the immune system, thus alternately explaining elevated levels of sCD14 and other biomarkers used as surrogates for microbial translocation \[[@R33]--[@R35]\]. Therefore, we measured relationships between plasma viremia and each of the biomarkers we studied during chronic infection ([Figure 4](#F4){ref-type="fig"}). In PTs HMGB1 was actually negatively correlated with plasma viremia ([Figure 4B](#F4){ref-type="fig"}), while in humans RAGE levels positively correlated ([Figure 4C](#F4){ref-type="fig"}). However, these associations were not observed across all three primate species and we found no associations between plasma viremia and either sCD14 ([Figure 4A](#F4){ref-type="fig"}) or IFABP ([Figure 4D](#F4){ref-type="fig"}). These data argue against plasma viremia (either directly or indirectly) leading to altered levels of these biomarkers.

![**Plasma biomarker associations with plasma viral load.** (A-E) Correlational analyses between SIV or HIV plasma viral load during chronic infection and plasma biomarkers in humans (black), RMs (red), and PTs (blue) for (A) sCD14, (B) HMGB1, (C) RAGE), (D) IFABP, and (E) Zonulin. All associations were analyzed using the Spearman rank test.](pai-5-068-g004){#F4}

DISCUSSION
==========

Microbial translocation is a well described phenomenon in chronically infected PLWH and SIV-infected Asian macaques \[[@R1], [@R3], [@R20]\]. Even after decades of ART - particularly if ART was initiated when nadir CD4^+^ T cell counts in peripheral blood were low - the damage that had occurred to the GI tract is not completely reversed, \[[@R30], [@R36], [@R37]\]. Residual inflammation which occurs in these treated individuals leads to increased mortality from different malignancies and cardiovascular disease and may be attributed, at least partially, to ongoing microbial translocation \[[@R11], [@R30], [@R38], [@R39]\]. While the current World Health Organization\'s recommendations are to initiate therapy as early as possible in all PLWH \[[@R40]\], most PLWH currently taking ART did not initiate therapy until the chronic phase of infection. These individuals may benefit from supplemental therapies which restore the GI tract and reduce microbial translocation and inflammation. Thus, there is a great need to identify putative biomarkers which can be used to monitor efficacy of strategies aimed at reducing microbial translocation and inflammation. Of the numerous plasma analytes which might fulfill this purpose, sCD14 is, by far, most frequently studied. Although sCD14 levels represent bioactivity of microbial products, several studies have shown that sCD14 levels can be elevated in the apparent absence of microbial translocation \[[@R22], [@R24]\]. While CD14 is, indeed, a specific receptor for LPS, HMGB1 is also a ligand for CD14 \[[@R25]--[@R27]\].

Here we sought to determine how levels of particular plasma biomarkers associated with microbial translocation and inflammation change over the course of SIV infection of NHPs and after administration of ARTs in HIV-1-infected individuals. We also sought to determine whether HMGB1 and RAGE might contribute to the elevated plasma levels of sCD14 observed in progressive HIV/SIV infections. Our data suggest that HMGB1 and RAGE are not associated with elevated levels of sCD14 observed in PLWH and SIV-infected NHPs given that neither HMGB1 nor RAGE levels reliably changed over time as NHPs became SIV-infected or PLWH initiated ARTs. Thus, elevated sCD14 is unlikely to be attributed to cellular death in these cases. We also do not find evidence that markers of intestinal epithelial damage correlate with sCD14, suggesting that these epithelial markers themselves are not sufficient biomarkers of microbial translocation and epithelial turnover after administration of ART could contribute to elevated levels of IFABP.

There is significant interest in understanding the mechanisms underlying microbial translocation, the degree to which microbial translocation contributes to inflammation observed in PLWH, and in developing therapeutic interventions which ameliorate microbial translocation \[[@R3], [@R41]--[@R43]\]. Assays to detect bacterial products in plasma lack sensitivity and reproducibility and assays to measure bacterial products in tissue require invasive procedures. While our study included a small cohort of NHPs and PLWH, and would have benefitted from inclusion of tissue biopsies, we believe our study demonstrates that measurement of sCD14 in plasma in conjunction with proteins which are released into circulation when GI tract epithelial cells are damaged (IFABP and zonulin) are currently the best available surrogates of systemic microbial translocation. We also believe that tissue measurement of microbial products remains the most robust measurement of microbial translocation. As next generation sequencing approaches become more available and accessible, the ability to detect nucleic acids corresponding to microbes in circulation may alleviate these issues \[[@R44]\].
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Study Participants -- PWH

  ID                  Timepoint   Plasma Viremia[^a^](#tab1fn1){ref-type="table-fn"}   CD4^+^ count[^b^](#tab1fn2){ref-type="table-fn"}   Sex      Age       Race/Ethnicity                      Tobacco Use   Albumin Levels[^c^](#tab1fn3){ref-type="table-fn"}
  ------------------- ----------- ---------------------------------------------------- -------------------------------------------------- -------- --------- ----------------------------------- ------------- ----------------------------------------------------
  1                   HIV+ ARV−   6,810                                                0                                                  Female   25        African American                    No            3.5
  HIV+ ARV+ (4 yrs)   \<40        542                                                  29                                                 4.0                                                                  
  2                   HIV+ ARV−   26,202                                               45                                                 Female   37        African American                    No            3.0
  HIV+ ARV+ (4 yrs)   \<40        510                                                  41                                                 4.2                                                                  
  3                   HIV+ ARV−   266,478                                              35                                                 Male     41        Multiple Races/Hispanic or Latino   No            3.9
  HIV+ ARV+ (4 yrs)   \<50        298                                                  45                                                 3.7                                                                  
  4                   HIV+ ARV−   28,432                                               33                                                 Male     39        African American                    No            3.8
  HIV+ ARV+ (4 yrs)   \<40        571                                                  43                                                 4.3                                                                  
  5                   HIV+ ARV−   6,842                                                12                                                 Female   41        African American                    No            2.8
  HIV+ ARV+ (4 yrs)   \<50        322                                                  45                                                 3.6                                                                  
  6                   HIV+ ARV−   116,716                                              44                                                 Male     53        African American                    Yes           3.3
  HIV+ ARV+ (4 yrs)   \<40        241                                                  57                                                 3.3                                                                  
  7                   HIV+ ARV−   \<50                                                 82                                                 Male     25        African American                    Yes           3.7
  HIV+ ARV+ (4 yrs)   \<40        353                                                  29                                                 4.1                                                                  
  8                   HIV+ ARV−   601,301                                              5                                                  Male     27        Caucasian/Hispanic or Latino        No            2.7
  HIV+ ARV+ (4 yrs)   \<40        347                                                  31                                                 4.3                                                                  
  9                   HIV+ ARV−   240,966                                              43                                                 Female   32        African American                    No            4.0
  HIV+ ARV+ (4 yrs)   \<40        759                                                  36                                                 3.7                                                                  
  10                  HIV+ ARV−   231,414                                              3                                                  Male     31        African American                    No            3.0
  HIV+ ARV+ (4 yrs)   \<40        547                                                  36                                                 4.0                                                                  
  11                  HIV+ ARV−   25,831                                               16                                                 Male     31        Caucasian/Hispanic or Latino        Yes           3.4
  HIV+ ARV+ (4 yrs)   60          172                                                  35                                                 3.7                                                                  
  12                  HIV+ ARV−   28,342                                               6                                                  Female   35        African American                    No            2.5
  HIV+ ARV+ (4 yrs)   \<40        605                                                  39                                                 3.8                                                                  
  13                  HIV+ ARV−   186,674                                              231                                                Male     40        Caucasian/Hispanic or Latino        No            2.2
  HIV+ ARV+ (4 yrs)   \<40        195                                                  44                                                 4.6                                                                  
  14                  HIV+ ARV−   379,425                                              7                                                  Female   25        Multiple Races/Hispanic or Latino   No            3.1
  HIV+ ARV+ (4 yrs)   \<40        588                                                  29                                                 4.1                                                                  
  15                  HIV+ ARV−   149,655                                              45                                                 Male     46        Caucasian/Hispanic or Latino        Yes           4.0
  HIV+ ARV+ (4 yrs)   \<40        238                                                  50                                                 4.2                                                                  
  16                  HIV+ ARV−   145,610                                              18                                                 Female   46        Caucasian/Hispanic or Latino        No            3.9
  HIV+ ARV+ (4 yrs)   \<40        149                                                  50                                                 4.6                                                                  
  17                  HIV+ ARV−   10,603                                               12                                                 Male     37        Multiple Races/Hispanic or Latino   No            2.6
  HIV+ ARV+ (4 yrs)   \<50        167                                                  41                                                 3.6                                                                  
  18                  HIV+ ARV−   \<50                                                 18                                                 Female   31        Caucasian/Hispanic or Latino        No            2.6
  HIV+ ARV+ (4 yrs)   \<40        352                                                  35                                                 3.9                                                                  
  19                  HIV+ ARV−   9,251                                                74                                                 Female   55        African American                    No            3.6
  HIV+ ARV+ (4 yrs)   \<40        291                                                  59                                                 3.9                                                                  
  20                  HIV+ ARV−   142,379                                              11                                                 Male     41        Caucasian/Hispanic or Latino        No            4.0
  HIV+ ARV+ (4 yrs)   \<40        368                                                  45                                                 4.4                                                                  
  21                  HIV+ ARV−   128,742                                              12                                                 Male     41        African American                    No            3.4
  HIV+ ARV+ (4 yrs)   \<50        258                                                  45                                                 4.0                                                                  
  22                  HIV+ ARV−   212,286                                              74                                                 Male     34        Unknown/Hispanic or Latino          Yes           3.4
  HIV+ ARV+ (4 yrs)   \<50        644                                                  39                                                 4.1                                                                  
  23                  HIV+ ARV−   339,630                                              12                                                 Female   32        Caucasian/Hispanic or Latino        No            3.7
  HIV+ ARV+ (4 yrs)   \<40        630                                                  36                                                 4.2                                                                  
  24                  HIV+ ARV−   71,873                                               6                                                  Female   33        African American                    No            3.4
  HIV+ ARV+ (4 yrs)   \<40        503                                                  37                                                 3.9                                                                  
  25                  HIV+ ARV−   609,435                                              124                                                Male     48        African American                    No            3.6
  HIV+ ARV+ (4 yrs)   \<40        212                                                  52                                                 4.0                                                                  
  26                  HIV+ ARV−   45,764                                               24                                                 Male     35        Caucasian/Hispanic or Latino        No            3.7
  HIV+ ARV+ (4 yrs)   \<40        361                                                  39                                                 4.3                                                                  
  27                  HIV+ ARV−   43,907                                               12                                                 Female   29        African American                    Yes           3.7
  HIV+ ARV+ (4 yrs)   \<40        349                                                  33                                                 4.1                                                                  
  28                  HIV+ ARV−   15,269                                               12                                                 Female   43        African American                    No            4.2
  HIV+ ARV+ (4 yrs)   \<40        347                                                  47                                                 4.3                                                                  
  29                  HIV+ ARV−   15,000                                               362                                                Male     24        Caucasian                           Yes           ND
  HIV+ ARV+ (1 yr)    \<50        457                                                  25                                                 ND                                                                   
  30                  HIV+ ARV−   10,600                                               182                                                Female   47        African American                    Yes           ND
  HIV+ ARV+ (1 yr)    \<400       400                                                  48                                                 ND                                                                   
  31                  HIV+ ARV−   4,620                                                444                                                Female   49        African American                    Yes           ND
  HIV+ ARV+ (1 yr)    \<50        291                                                  50                                                 ND                                                                   
  32                  HIV+ ARV−   7,870                                                372                                                Male     34        African American                    Unknown       ND
  HIV+ ARV+ (1 yr)    \<50        319                                                  35                                                 ND                                                                   
  33                  HIV+ ARV−   216,000                                              113                                                Male     Unknown   Caucasian                           No            ND
  HIV+ ARV+ (1 yr)    \<48        323                                                  ND                                                                                                                      
  34                  HIV+ ARV−   17,700                                               45                                                 Female   34        African American                    Yes           ND
  HIV+ ARV+ (1 yr)    ND          ND                                                   35                                                 ND                                                                   

Plasma viral load (copies/mL)

CD4+ T cell count (cells/ul blood)

Plasma albumin levels (g/dL)

###### 

Study Participants -- Pigtail Macaques

  ID            Timepoint   Plasma Viremia[^a^](#tab2fn1){ref-type="table-fn"}   CD4+ count[^b^](#tab2fn2){ref-type="table-fn"}   Sex      Age   Albumin Levels[^c^](#tab2fn3){ref-type="table-fn"}
  ------------- ----------- ---------------------------------------------------- ------------------------------------------------ -------- ----- ----------------------------------------------------
  PT98P030      Pre-SIV     0                                                    976                                              Female         
  Acute SIV     1,736       ND                                                                                                                   
  Chronic SIV   621         372                                                  11.5                                             ND             
  PTA0P039      Pre-SIV     0                                                    1,144                                            Female         
  Acute SIV     1,767,348   230                                                                                                                  
  Chronic SIV   19,161      45                                                   9.5                                              3.6            
  PT99P052      Pre-SIV     0                                                    1,597                                            Female         
  Acute SIV     331,131     ND                                                                                                                   
  Chronic SIV   643,458     30                                                   10.5                                             3.2            
  PT99P029      Pre-SIV     0                                                    765                                              Female         
  Acute SIV     475,587     355                                                                                                                  
  Chronic SIV   5,394,895   8                                                    10.8                                             2.3            
  PT98P005      Pre-SIV     0                                                    765                                              Female         
  Acute SIV     323,594     203                                                                                                                  
  Chronic SIV   7,625       33                                                   12                                               2.1            
  PT99P030      Pre-SIV     0                                                    842                                              Female         
  Acute SIV     103558      369                                                                                                                  
  Chronic SIV   6,600       372                                                  11.2                                             3.8            
  PTA0P007      Pre-SIV     0                                                    653                                              Female         
  Acute SIV     125,440     199                                                                                                                  
  Chronic SIV   43,311      31                                                   10                                               3.5            
  PTA1P012      Pre-SIV     0                                                    1,347                                            Female         
  Acute SIV     355,277     387                                                                                                                  
  Chronic SIV   201,583     160                                                  9.2                                              4.1            
  PTA0P012      Pre-SIV     0                                                    690                                              Female         
  Acute SIV     2,403,815   154                                                                                                                  
  Chronic SIV   226,244     37                                                   19.9                                             4              

Plasma viral load (copies/mL)

CD4+ T cell count (cells/ul blood)

Plasma albumin levels at chronic timepoint (g/dL)

ND = not done

###### 

Study Participants -- Rhesus macaques

  ID            Timepoint   Plasma Viremia[^a^](#tab3fn1){ref-type="table-fn"}   CD4+ count[^b^](#tab3fn2){ref-type="table-fn"}   Sex    Age   Albumin Levels[^c^](#tab3fn3){ref-type="table-fn"}
  ------------- ----------- ---------------------------------------------------- ------------------------------------------------ ------ ----- ----------------------------------------------------
  RHCL4C        Pre-SIV     0                                                    158                                              Male         
  Acute SIV     873,043     219                                                                                                                
  Chronic SIV   840,000     47                                                   14                                               2.8          
  RHCL7P        Pre-SIV     0                                                    886                                              Male         
  Acute SIV     612,776     1,012                                                                                                              
  Chronic SIV   560,000     ND                                                   14.3                                             3.6          
  RHCL86        Pre-SIV     0                                                    1,037                                            Male         
  Acute SIV     1,471,247   251                                                                                                                
  Chronic SIV   1,100,000   91                                                   14                                               3.4          
  RHDCBC        Pre-SIV     0                                                    446                                              Male         
  Acute SIV     133,266     454                                                                                                                
  Chronic SIV   1,200,000   ND                                                   8.4                                              2.8          
  RHDCJWA       Pre-SIV     0                                                    730                                              Male         
  Acute SIV     556,021     195                                                                                                                
  Chronic SIV   700,000     ND                                                   8.3                                              2.6          
  RHDCKJ        Pre-SIV     0                                                    966                                              Male         
  Acute SIV     627,870     853                                                                                                                
  Chronic SIV   5,300,000   192                                                  8.1                                              3.8          
  RHDCVF        Pre-SIV     0                                                    410                                              Male         
  Acute SIV     178,242     160                                                                                                                
  Chronic SIV   7,200,000   268                                                  7                                                3.5          
  RHDE1A        Pre-SIV     0                                                    339                                              Male         
  Acute SIV     557,837     182                                                                                                                
  Chronic SIV   200,000     ND                                                   7.8                                              3.4          
  RHDE20        Pre-SIV     0                                                    747                                              Male         
  Acute SIV     709,493     304                                                                                                                
  Chronic SIV   67,000      ND                                                   7.5                                              3.6          
  RHDE2C        Pre-SIV     0                                                    454                                              Male         
  Acute SIV     12,688      154                                                                                                                
  Chronic SIV   470,000     ND                                                   7.4                                              3.4          
  RHDE2W        Pre-SIV     0                                                    297                                              Male         
  Acute SIV     66,799      165                                                                                                                
  Chronic SIV   920,000     93                                                   7                                                2.1          

Plasma viral load (copies/mL)

CD4+ T cell count (cells/ul blood)

Plasma albumin levels at chronic timepoint (g/dL)

ND = not done
